Knockdown of long non-coding MIR210HG inhibits cell proliferation, migration, and invasion in hepatoblastoma via the microRNA-608–FOXO6 axis

Yuhe Duan¹, He Wu², Xiwei Hao¹, Fujiang Li¹, Jie Liu³, Chengzhan Zhu⁴ and Qian Dong¹,³

Abstract

Objective: Hepatoblastoma is the most common liver tumor. Recent research has found that long non-coding (lnc)RNAs are involved in multiple types of cancers, but the potential mechanism of lncRNA MIR210HG in hepatoblastoma remains unknown. The present study explored the molecular mechanism of MIR210HG in hepatoblastoma progression.

Methods: The cell counting kit-8 was used to detect cell viability, and Transwell assays assessed cell migration and invasion. Luciferase reporter assays showed the relationship between MIR210HG and microRNA (miR)-608 and between miR-608 and forkhead box O6 (FOXO6). Functional tests were verified in vivo by a tumor xenograft model. The expression of MIR210HG, miR-608, FOXO6, E-cadherin, N-cadherin, and vimentin was determined by quantitative reverse transcription polymerase chain reaction and western blotting.

Results: MIR210HG was shown to be highly expressed in hepatoblastoma tissues and cell lines. Knockdown of MIR210HG reduced proliferation, migration, and invasion in liver cancer cells, and suppressed tumor growth in vivo. MIR210HG competitively combined with miR-608, and miR-608 decreased FOXO6 expression.

¹Department of Pediatric Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
²Department of Pediatric Surgery, Qingdao Women and Children’s Hospital, Qingdao, China
³Shandong Key Laboratory of Digital Medicine and Computer Assisted Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
⁴Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China

Corresponding author:
Qian Dong, Department of Pediatric Surgery, Shandong Key Laboratory of Digital Medicine and Computer Assisted Surgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Shinan District, Qingdao 266003, China.
Email: dongqianqd@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Conclusion: Our study demonstrated that knockdown of MIR210HG inhibits hepatoblastoma development through binding to miR-608 and downregulating FOXO6. Our results provide novel insights for hepatoblastoma treatment involving the MIR210HG–miR608–FOXO6 axis.

Keywords
MIR210HG, microRNA-608, forkhead box O6, hepatoblastoma, cell proliferation, cell migration, cell invasion

Date received: 6 April 2021; accepted: 1 October 2021

Introduction
Hepatoblastoma is the most common primary liver tumor found in children, accounting for 65% of pediatric liver malignancies and predominantly occurring before the age of 2 years.1 It usually involves the transformation of immature liver precursor cells, and is not associated with hepatitis virus infection or hepatocirrhosis.2 Standard treatments for primary hepatoblastoma include complete resection, neoadjuvant chemotherapy, and liver transplantation.3 Patients whose hepatoblastomas are completely resected have a high survival rate; however, those with unresectable metastatic hepatoblastoma have a poor prognosis and low survival rate.4 Therefore, there is a need to develop effective diagnostic biomarkers to identify patients with hepatoblastoma early and to explore the mechanism of hepatoblastoma.

Long non-coding (Inc)RNAs are transcribed RNA molecules up to 200 nucleotides in length that do not encode proteins. Recent studies have found that IncRNAs have a range of functions in cancer, including in angiogenesis, tumorigenesis, and tumor metastasis.5 Moreover, genome-wide analysis showed a difference in the expression of IncRNAs between hepatoblastoma and healthy liver tissue.6 MIR210HG is encoded by the MIR210 host gene and has been shown to function in colon cancer, invasive breast cancer, and non-small cell lung cancer.6–8 Additionally, Yan et al reported that MIR210HG is an oncogenic IncRNA in hepatocellular carcinoma (HCC), suggesting it has the potential to be a biomarker for hepatoblastoma in clinical diagnoses.9 However, the function of MIR210HG in hepatoblastoma is poorly understood. In this study, we explored the mechanism underlying the role of MIR210HG in hepatoblastoma, and show that it affected the proliferation, migration, and invasion of HuH-6 cells via the microRNA (miR)-608/Forkhead box (FOX)O6 axis.

Materials and methods
Samples
Thirty human hepatoblastoma tissue samples and adjacent healthy liver tissue samples were obtained from patients undergoing resection surgery at the Affiliated Hospital of Qingdao University. The present study followed the guidelines of The Declaration of Helsinki, and all patients provided their written informed consent. Tissue samples were immediately kept in liquid nitrogen and then stored at −80°C for further analysis. This study was approved by the ethics committee of the Affiliated Hospital of Qingdao University (approval number SYFY-WALL-25777).
Cell culture

Human hepatoblastoma cell lines SSMC-7721 and HuH-6, and HepG2, and the human normal liver cell line L-02 were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) mixed with 10% fetal bovine serum (FBS, Gibco) and 1% antibiotics (streptomycin and penicillin; Sigma-Aldrich, St Louis, MO, USA) in a humidified incubator with 5% CO2 at 37°C. HuH-6 and HepG2 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and SSMC-7721 and L02 cells were from the Shanghai Institute of Cell Biology (Chinese Academy of Sciences, Shanghai, China).

Short hairpin and small interfering RNA transfection

MIR210HG short hairpin RNA (shRNA) and negative control shRNA were purchased from Genepharma (Shanghai, China). The target sequence was 5'-GAGGAGGGACGCUGCGGCGTG-3'. Cells were transfected with MIR210HG shRNA or NC shRNA using Lipofectamine RNAiMAX transfection reagent according to the manufacturer’s instructions (Thermo Fisher Scientific).

A negative control siRNA (inh-NC) was also used to control for nonspecific binding. Four groups of HepG2 cells were transfected with sh-NC + inh-NC, sh-MIR210HG + inh-NC, sh-NC + miR-608 inhibitor, and sh-MIR210HG + miR-608 inhibitor using Lipofectamine 3000.

Quantitative reverse transcription polymerase chain reaction (RT-qPCR)

Total RNA was extracted from cells and tissues using TRIzol reagent according to the manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific), and cDNA synthesis was performed using the PrimeScript RT Reagent Kit with gDNA Eraser following the manufacturer’s instructions (Takara Biotechnology, Dalian, China). Briefly, 1 µg RNA was combined with 2 µl 5 × RNA reverse transcriptase in DEPC water to 10 µl, then incubated at 40°C for 15 minutes and 85°C for 5 s. RT-qPCR was carried out using 0.2 µl cDNA, 10 µl SYBR Green Premix Ex Taq kit (Takara Biotechnology), 0.5 µl forward primer, 0.5 µl reverse primer, and DEPC water to 20 µl on an ABI 7500 real-time RT-PCR system (Applied Biosystems, Thermo Fisher Scientific). PCR conditions were 95°C for 30 s, then 40 cycles of 95°C for 5 s and 60°C for 30 s.

Primer sequences were: MIR210HG forward primer 5'-GCTTGGTAGAGTGTCACGCC-3', reverse primer 5'-CATCTGACCGACGGGCGGCTCCGTA-3', reverse primer 5'-CATCTGACCGACGGGCGGCTCCGTA-3'; miR-608 forward primer 5'-GGTGTTGGGACAGCTCGTGACC-3', reverse primer 5'-CCCTCCAGGGGATCTGGTTTGG-3'; FOXO6 forward primer 5'-GGCCGCGCTCGTGTACC-3', reverse primer 5'-ATACAGAGTACTTTGCTGGTGACGCGGCGGCGGCGG-3'; GAPDH forward primer 5'-AATGGACAACTGGTGGAC-3', reverse primer 5'-TACAGAGTACTTTGCTGGTGACGCGGCGGCGGCGGCGG-3'; and U6 forward primer 5'-GCCAGCGGCTCTTCGTT-3', reverse primer 5'-AGCCTGACTTGCTAGTGGATTAT-3'.

Data analysis used the 2−ΔΔCt method and gene expression was normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for MIR210HG and FOXO6, and U6 for miR-608.

Cell viability assay

The cell counting kit (CCK)-8 kit (Dojindo, Kumamoto, Japan) was used to determine cell viability. Hepatoblastoma cells were seeded at 1 × 10⁴ cells/well in a 96-well plate. After the required treatments, they were cultured with CCK-8 according to the manufacturer’s instructions. After 2 hours,
their optical density at 450 nm was detected using a microplate reader.

**Transwell assay**

Twelve-well culture plates with 8-µm micropore inserts (Corning Inc., Corning, NY, USA) were used for Transwell cell migration assays. After the required treatments, 3 x 10^4 hepatoblastoma cells were suspended in 200 µL FBS-free DMEM medium and cultured in the upper compartment of the chamber. A total of 600 µL DMEM medium mixed with 20% FBS was applied to the lower compartment. Cells were cultured for 48 hours, then those that attached to the lower surface of the chamber were fixed with ethanol and stained with 0.5% crystal violet. Cells in five random fields of view were counted under the microscope.

The same 12-well culture plates with 8-µm micropore inserts were used for cell invasion assays, and the top side of the insert was coated with Matrigel. The same procedure as described above for the cell migration assay was followed.

**Vector construction**

Wild-type or mutant sequences of MIR210HG (Figure 1a) or FOXO6 (Figure 2a) containing miR-608 binding sites were amplified, digested, and ligated into the pGL3 luciferase vector (Promega, Madison, WI, USA) to investigate the binding between MIR210HG or FOXO6 with miR-608.

**Dual luciferase reporter assay**

The indicated luciferase reporter vector and appropriate miRNA (MIR210HG-WT, MIR210HG-MUT, FOXO6-WT, or FOXO6-MUT) were transfected into human hepatoblastoma cells using Lipofectamine 3000 according to the manufacturer’s instructions (Thermo Fisher Scientific). After 72 hours of incubation,

---

**Figure 1.** Dual luciferase assay showing that miR-608 targets MIR210HG. (a) Bioinformatics analysis predicted that MIR210HG binds with miR-608. (b) RT-qPCR showing that MIR210HG decreased the expression of miR-608 in HuH-6 and HepG2 cells. (c, d) Dual-luciferase reporter assay showing that MIR210HG binds miR-608 in HuH-6 and HepG2 cells. **p < 0.01, ***p < 0.001, ns, not significant. miR, microRNA; RT-qPCR, quantitative reverse transcription polymerase chain reaction.
the cells were harvested by passive lysis buffer (Promega). Luciferase activity was determined using a dual luciferase assay kit (Promega).

**Western blotting**

Cells were harvested using radioimmunoprecipitation assay lysis buffer and centrifuged at 13,500 × g for 20 minutes at 4°C. Supernatants were collected in Eppendorf tubes, and protein concentrations determined using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology, Shanghai, China). Equal amounts of protein samples were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were incubated with the primary antibody at 4°C overnight, then incubated with the secondary antibody for 2 hours at room temperature. Primary antibodies were: anti-FOXO6 (dilution 1:1000), anti-E-cadherin (dilution 1:1000), anti-N-cadherin (dilution 1:1000), and anti-vimentin (dilution 1:1000); secondary antibodies were: anti-rabbit (dilution 1:2000), and anti-mouse (dilution 1:2000). All antibodies were from Abcam (Cambridge, MA, USA). Protein blots were visualized using ECL chemiluminescence with GAPDH as a loading control.

**Colony forming assay**

After transfection, HuH-6 and HepG2 cells (1 × 10³ per well) were seeded in 6-well plates and grown for 2 weeks in a humidified incubator at 37°C with 5% CO₂. They were then washed with phosphate-buffered saline (Corning Inc.), fixed with 4% paraformaldehyde (Sigma-Aldrich) and stained with 0.5% crystal violet (Solarbio Science &
Technology, Beijing, China) for 10 minutes. Colonies with more than 50 cells were counted using a microscope (Olympus, Tokyo, Japan).

**Tumor xenograft model**

Thirty-six 4-week-old female nude mice (Shanghai Laboratory Animal Center of Chinese Academy of Sciences, Shanghai, China) were raised in a specific pathogen-free animal room and allowed access to feed and water *ad libitum*. We established a HUH-6 cell line stably expressing shRNA-MIR210HG (MIR KD). We first designed the MIR210HG interference sequence and ligated this into the pGPU6/GFP/Neo expression vector to construct the shRNA-MIR210HG plasmid and negative control plasmid. The shRNA-MIR210HG plasmid was transfected into HUH-6 cells using Lipofectamine 3000, then cells were screened with G418 resistance for 14 days to obtain a cell line stably expressing shRNA-MIR210HG. A total of $3 \times 10^5$ MIR KD or HUH-6 cells were subcutaneously injected into the right back of mouse flanks. Tumors were removed 32 days after transplant and their diameters were measured.

**Bioinformatics analysis**

We used RegRNA2.0 (http://regrna2.mbc.nctu.edu.tw/) to identify miRNAs capable of binding MIR210HG.

We also used the TargetScanHuman 6.2 database (http://www.targetscan.org/vert_61/) to predict potential mRNA targets of miR-608.

**Research statement**

This study followed guidelines for REporting recommendations for tumour MARKer prognostic studies (REMARK). All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (2011).10

**Statistical analysis**

Data are presented as means ± S.E.M from at least three independent experiments. Comparisons between groups were analyzed using the Student’s t test with SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). $P < 0.05$ was considered to be statistically significant.

**Results**

**MIR210HG is upregulated in hepatoblastoma tissues and cells**

RT-qPCR analysis showed that MIR210HG expression was significantly upregulated in 30 pairs of hepatoblastoma tissues compared with adjacent healthy liver tissues ($p < 0.001$; Figure 3a). Moreover, MIR210HG expression was also significantly higher in hepatoblastoma cells compared with non-malignant L-02 hepatocytes ($p < 0.01$; Figure 3b). These results indicate that MIR210HG is a potential regulator involved in hepatoblastoma progression.

**Knockdown of MIR210HG suppressed cell proliferation, migration, and invasion in HuH-6 and HepG2 cells**

We found that MIR210HG expression was higher in HuH-6 and HepG2 cells than in SSMC-7721 cells (Figure 3b). Here, to investigate the function of MIR210HG in hepatoblastoma *in vitro*, we designed a MIR210HG shRNA which we transfected into hepatoblastoma cells. RT-qPCR revealed that MIR210HG shRNA transfection significantly reduced MIR210HG expression in HuH-6 and HepG2 cells ($p < 0.001$; Figure 4a). The CCK-8 assay showed that silencing of MIR210HG...
significantly suppressed cell viability in HuH-6 (p < 0.05) and HepG2 (p < 0.01) cells (Figure 4b), while the colony formation assay showed similarly significant suppression of proliferation in HuH-6 and HepG2 cells (p < 0.01; Figure 4c, d). Moreover, the Transwell assay revealed that MIR210HG silencing significantly suppressed the migration (p < 0.01) and invasion (p < 0.001) of HepG2 and HuH-6 cells compared with the sh-NC transfected group (Figure 4e–h).

**Knockdown of MIR210HG inhibited tumor growth in vivo**

To understand the role of MIR210HG in hepatoblastoma in vivo, we used a mouse HUH-6 cell xenograft model to investigate the effect of MIR210HG on tumor growth. Tumor size was measured every 8 days (Figure 5) and shown to be reduced in the MIR210HG knockdown group compared with the control group, suggesting that MIR210HG influences tumor growth in vivo.

**MIR210HG regulated miR-608 expression in HuH-6 and HepG2 cells**

Fifteen miRNAs were predicted to bind with MIR210HG. We selected miR-608 for further study because it is a known tumor suppressor. Bioinformatics was used to predict the seed region of miR-608 in mutated and wild-type MIR210HG. The miR-608 fragment 5'-UGCCUCGACAG GGUUGUGGGAGA-3' paired well with 5'-GAGGAGGGTCCCAGCGGCCCT-3' located in MIR210HG (Figure 1a). RT-qPCR showed that MIR210HG significantly decreased the expression of miR-608 in HuH-6 and HepG2 cells (p < 0.001; Figure 1b). To avoid non-specific binding, we mutated the miR-608 binding site of MIR210HG from 5'-GAGGAGGGTCCCAGCGGCCCT-3' to 5'-GAGGAGGGTCCCAGCGGCCCT-3', to generate RLuc-MIR210HG-Mut. MIR210HG cDNA was integrated downstream of the luciferase gene (RLuc-MIR210HG-WT) and transfected into HuH-6 and HepG2 cells with different miRNA mimics (Figure 1c, d). RLuc-MIR210HG-WT expression was
Figure 4. Knockdown of MIR210HG suppressed proliferation, migration, and invasion in HuH-6 and HepG2 cells. (a) RT-qPCR analysis of MIR210HG expression in HuH-6 and HepG2 cells transfected with sh-NC or sh-MIR210HG IncRNA vectors. (b) CCK-8 analysis of HuH-6 or HepG2 cells expressing the corresponding vector. (c, d) HuH-6 and HepG2 cells show reduced proliferation after MIR210HG depletion using the colony formation assay. (e, f) The Transwell assay showing reduced migration in HuH-6 and HepG2 cells after depleting MIR210HG. (g, h) The Transwell assay showing reduced invasion in HuH-6 and HepG2 cells after depleting MIR210HG. *p < 0.05, **p < 0.01, ***p < 0.001.

miR, microRNA; RT-qPCR, quantitative reverse transcription polymerase chain reaction; sh, short hairpin; lnc, long non-coding; CCK, cell counting kit.
significantly reduced by the miR-608 mimic in HepG2 (p < 0.001) and HuH-6 cells (p < 0.01), but the miR-608 mimic had no effect on RLuc-MIR210HG-mut expression. These data suggest that miR-608 directly regulates MIR210HG expression in HuH-6 and HepG2 cells.

**miR-608 inhibition abolished the effect of sh-MIR210HG in HuH-6 and HepG2 cells**

To determine whether miR-608 abolished the function of sh-MIR210HG in HepG2 cells, we designed an miR-608 inhibitor to inhibit its binding with sh-MIR210HG. The CCK-8 assay showed that silencing of miR-608 significantly promoted cell viability in HuH-6 and HepG2 cells (p < 0.001; Figure 6a, b). The colony formation assay also showed that silencing of miR-608 significantly promoted cell proliferation in HuH-6 (p < 0.01; Figure 6c, e) and HepG2 cells (p < 0.001; Figure 6d, f). Moreover, the Transwell assay revealed that miR-608 silencing significantly promoted the migration and invasion of HuH-6 (p < 0.01; Figure 6g, i, k, m) and HepG2 cells (p < 0.001; Figure 6h, j, l, n) compared with control groups. Collectively, these results show that inhibiting the function of miR-608 abolished the effect of sh-MIR210HG in HuH-6 and HepG2 cells.

**MIR210HG regulated the expression of FOXO6 in HuH-6 and HepG2 cells**

Among the predicted mRNA targets of miR-608, we focused on the transcription factor FOXO6, whose expression is promoted in many cancer cells such as those of gastric cancer, non-small cell lung cancer, and HCC. To determine whether FOXO6 is a downstream target of miR-608, the wild-type or mutant 3'-untranslated region (UTR) of FOXO6 was cloned into the luciferase coding region of the pGL3 vector and transfected into HuH-6 and HepG2 cells with miR-608 mimics or a negative control mimic (Figure 2a). miR-608 overexpression significantly reduced the luciferase reporter activity of wild-type, but not mutant, FOXO6 (p < 0.001; Figure 2b, c).

To investigate whether miR-608 affects the relative concentration of FOXO6, we used RT-qPCR to measure FOXO6 mRNA expression. miR-608 knockdown significantly increased mRNA expression of FOXO6 (p < 0.01), while miR-608 overexpression significantly decreased FOXO6 mRNA levels (p < 0.001) (Figure 2d, e). Western blotting showed that miR-608 mimics significantly downregulated protein levels of FOXO6 in HuH-6 and HepG2 cells (p < 0.05), whereas miR-608 knockdown increased FOXO6 protein levels in HuH-6 and HepG2 cells (p < 0.05 in HepG2 cells; Figure 2f–i). These results suggest that
miR-608 combines with FOXO6 to reduce its expression in HuH-6 and HepG2 cells.

**FOXO6 abolished the effect of sh-MIR210HG in HuH-6 and HepG2 cells**

To determine whether the MIR210HG–miR608–FOXO6 interaction could regulate hepatoblastoma cells in vitro, we constructed a pcDNA3.1-FOXO6 expression vector. The CCK-8 assay showed that FOXO6 overexpression significantly promoted cell viability in HuH-6 and HepG2 cells (p < 0.01; Figure 7a, b), while the colony formation assay showed that it significantly promoted proliferation in HuH-6 and HepG2 cells (p < 0.01; Figure 7c–f). Moreover, the Transwell assay revealed that FOXO6 overexpression significantly...
increased migration and invasion of HuH-6 (p < 0.001; Figure 7g, i, k, m) and HepG2 cells (p < 0.001; Figure 7h, j, l, n), abolishing the effect of sh-MIR210HG. Western blotting showed that sh-miR210HG significantly increased the protein expression of E-cadherin (p < 0.05) and significantly decreased that of N-cadherin (p < 0.01) and vimentin (p < 0.05) in HuH-6 cells, whereas this was partially restored when FOXO6 levels were increased (Figure 8a–d). These results suggest that the MIR210HG–miR608–FOXO6 network is critical for hepatoblastoma cell function.

**Discussion**

Hepatoblastoma is a common liver malignancy in children that is not associated with hepatitis virus infection or hepatocirrhosis.¹
The survival rates of patients with unresectable metastasis is notably lower than those with completely resected tumors. Therefore, understanding the mechanism of hepatoblastoma and developing novel biomarkers is important for clinical diagnosis.

The abnormal expression of lncRNAs has been identified in several human cancers, and lncRNAs have been reported to regulate a series of pathological processes, including cell growth, differentiation, and migration by functioning as tumor suppressors or oncogenes that regulate gene expression. The lncRNA MIR210 host gene (MIR210HG) is transcribed by gene ENSG00000247095.2, and was recently found to be associated with tumorigenesis. For example, Ruan et al. used the Cancer Genome Atlas database to analyze lncRNAs dysregulated in human colon cancers and found that MIR210HG was upregulated in colon cancer compared with healthy colon tissues. Moreover, Wang

Figure 8. The function of the MIR210HG–miR-608–FOXO6 axis in HUH-6 cell growth. (a–d) Western blots detecting the expression of E-cadherin, N-cadherin, and vimentin, using GAPDH as the internal control. *p < 0.05, **p < 0.01, ns, not significant.
et al reported higher miR210HG expression in HCC tumor tissues compared with para-cancerous tissues, indicating MIR210HG as a marker for poor prognosis in HCC. However, the expression and function of MIR210HG in hepatoblastoma are unclear.

In this study, RT-qPCR was used to show the significantly increased expression of MIR210HG in 30 pairs of hepatoblastoma tissues compared with adjacent healthy liver tissues; similar results were observed in hepatoblastoma cells and normal liver cell lines. We also found that miR210HG knockdown significantly suppressed tumor growth in vivo and significantly suppressed hepatoblastoma cell viability, proliferation, invasion, and migration in vitro.

Recent work has shown that lncRNAs act as competitive endogenous RNAs, which adsorb miRNAs and regulate physiological and pathological processes. Here, we used the bioinformatics database RegRNA 2.0 to predict the target miRNA of MIR210HG. miRNAs negatively regulate gene expression through binding mRNAs, and miR-608 was previously shown to regulate the expression of FOXO6, TEAD2, and other target proteins to influence cancer progression. We found that MIR210HG could bind miR-608 and reduce its expression in HepG2 cells. We also showed that miR-608 knockdown promoted hepatoblastoma cell viability, proliferation, invasion, and migration in vitro. These results indicate that MIR210HG binds miR-608 to regulate the progression of hepatoblastoma.

miR-608 was recently reported to act as an inhibitor in non-small cell lung cancer cells by regulating the expression of TEAD2. Additionally, Wang et al. found that miR-608 is associated with the risk of HCC in a large-scale population. Here, we found that FOXO6 mRNA is a potential target of miR-608. The downregulation of FOXO6 has been shown to inhibit proliferation, invasion, and glycolysis in colorectal cancer cells, while FOXO6 was also found to play an important role in HCC, especially in epithelial–mesenchymal transition (EMT). EMT is critical in the development of cancer through its effects on cancer cell proliferation, migration, and invasion, and the decreased expression of FOXO6 in breast cancer was previously reported to promote EMT, migration, and proliferation in cancer cells. In this work, we found that decreased expression of MIR210HG increased the protein expression of E-cadherin and decreased that of N-cadherin and vimentin, whereas this was partially restored when FOXO6 expression was increased or miR-608 levels decreased. These results indicate that EMT in human hepatoblastoma cells is regulated by the MIR210HG–miR608–FOXO6 axis.

No target drugs for MIR210HG, miR-608, or FOXO6 are currently in experimental or clinical trial stages, suggesting there is still relatively little research about their roles in cancers, so these should be further studied. In our future work, we aim to investigate the expression levels of MIR210HG, miR-608, and FOXO6 in the serum of patients with hepatoblastoma to determine whether the MIR210HG–miR-608–FOXO6 axis has an indicative effect on the prognosis of hepatoblastoma patients.

Conclusions

In this study, we demonstrated that MIR210HG was highly expressed in hepatoblastoma tissues and cell lines, and that the knockdown of MIR210HG inhibited hepatoblastoma development through binding to miR-608 and upregulating FOXO6. Our results suggest that the MIR210HG–miR-608–FOXO6 axis could be a novel target for hepatoblastoma treatment.
Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This work was supported by the China Association for Science and Technology (2013BAI01B03) and Qingdao Association for Science and Technology (14-6-1-6-zdzx).

ORCID iD
Qian Dong https://orcid.org/0000-0002-6826-338X

References
1. Sharma D, Subbarao G and Saxena R. Hepatoblastoma. Semin Diagn Pathol 2017; 34: 192–200.
2. Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26: 19–28.
3. Perilongo G, Malogolowkin M and Feusner J. Hepatoblastoma clinical research: lessons learned and future challenges. Pediatr Blood Cancer 2012; 59: 818–821.
4. Felsted AE, Shi Y, Masand PM, et al. Intraoperative ultrasound for liver tumor resection in children. J Surg Res 2015; 198: 418–423.
5. Lou W, Ding B, Zhong G, et al. Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer. Aging (Albany NY) 2019; 11: 11416–11439.
6. Dong R, Jia D, Xue P, et al. Genome-wide analysis of long noncoding RNA (lncRNA) expression in hepatoblastoma tissues. PLoS One 2014; 9: e85599.
7. Li XY, Zhou LY, Luo H, et al. The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer. Aging (Albany NY) 2019; 11: 5646–5665.
8. Kang X, Kong F, Huang K, et al. LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1. Onco Targets Ther 2019; 12: 3779–3790.
9. Wang Y, Li W, Chen X, et al. MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma. Biomed Pharmacother 2019; 111: 1297–1301.
10. Guide for the Care and Use of Laboratory Animals. US National Institutes of Health https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf (2011, accessed 3 November 2021).
11. Liang Z, Wang X, Xu X, et al. MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway. Mol Cancer 2017; 16: 96.
12. Othman N and Nagoor NH. miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2. Int J Oncol 2017; 51: 1757–1764.
13. Jiao H, Jiang S, Wang H, et al. Upregulation of LINC00963 facilitates melanoma progression through miR-608/NACC1 pathway and predicts poor prognosis. Biochem Biophys Res Commun 2018; 504: 34–39.
14. Qiu L, Tang Q, Li G, et al. Long non-coding RNAs as biomarkers and therapeutic targets: Recent insights into hepatocellular carcinoma. Life Sci 2017; 191: 273–282.
15. Wang Y, Li F, Ma D, et al. MicroRNA608 sensitizes nonsmall cell lung cancer cells to cisplatin by targeting TEAD2. Mol Med Rep 2019; 20: 3519–3526.
16. Ruan Z, Xu Z, Li Z, et al. Integral analyses of survival-related long non-coding RNA MIR210HG and its prognostic role in colon cancer. Oncol Lett 2019; 18: 1107–1116.
17. Bi X, Guo XH, Mo BY, et al. LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis. EBioMedicine 2019; 50: 408–420.
18. Miao Z, Guo X and Tian L. The long non-coding RNA NORAD promotes the growth
of gastric cancer cells by sponging miR-608. *Gene* 2019; 687: 116–124.

19. Wang R, Zhang J, Ma Y, et al. Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a largescale population. *Mol Med Rep* 2014; 10: 2736–2744.

20. Li Q, Tang H, Hu F, et al. Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells. *J Cell Biochem* 2019; 120: 3853–3860.

21. Zuo X, Chen Z, Cai J, et al. 5-Hydroxytryptamine receptor 1D aggravates hepatocellular carcinoma progression through FoxO6 in AKT-dependent and independent manners. *Hepatology* 2019; 69: 2031–2047.

22. Ota I, Masui T, Kurihara M, et al. Snail-induced EMT promotes cancer stem cell-like properties in head and neck cancer cells. *Oncol Rep* 2016; 35: 261–266.

23. Ye H and Duan M. Downregulation of FOXO6 in breast cancer promotes epithelial-mesenchymal transition and facilitates migration and proliferation of cancer cells. *Cancer Manag Res* 2018; 10: 5145–5156.